Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 12/20 | 0.43 |
| ▸ | CTSD | P07339 | 5/20 | 0.42 |
| ▸ | GRPR | P30550 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12767663 | 0.91 | REN (0.47) | RENCTSD | |
| SCHEMBL29473461 | 0.91 | CTSD (0.44) | RENCTSDGRPR | |
| SCHEMBL15444508 | 0.90 | CTSD (0.44) | RENCTSDGRPR | |
| SCHEMBL12767762 | 0.90 | REN (0.46) | RENCTSDGRPR | |
| SCHEMBL15444513 | 0.90 | CTSD (0.45) | RENCTSDGRPR | |
| SCHEMBL15444494 | 0.87 | REN (0.53) | RENCTSD | |
| SCHEMBL29556991 | 0.87 | REN (0.46) | RENCTSD | |
| SCHEMBL29473464 | 0.85 | REN (0.43) | RENCTSD | |
| SCHEMBL27644993 | 0.82 | GRPR (0.42) | GRPR | |
| SCHEMBL30118081 | 0.80 | REN (0.45) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215527-A2 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | NOVARTIS AG (CH) | 2025-10-16 | — | — | WO | disclosed |
| EP-4608458-A1 | IDENTIFICATION AND/OR TREATMENT OF CANCER | Clarity Pharmaceuticals Limited (AU) | 2025-09-03 | — | — | EP | disclosed |
| US-12103927-B2 | Pyclen-based macrocyclic ligands, chelates thereof and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-10-01 | — | — | US | disclosed |
| WO-2024086891-A1 | IDENTIFICATION AND/OR TREATMENT OF CANCER | Clarity Pharmaceuticals Limited (AU) | 2024-05-02 | — | — | WO | disclosed |
| EP-4273142-A1 | PICOLINATE CYCLAM PALLADIUM CHELATES AND USES THEREOF | Université de Bretagne Occidentale (FR) | 2023-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12103927-B2 | Pyclen-based macrocyclic ligands, chelates thereof and uses thereof | PYCR1, NPY1R, RXFP3 | REN 403/4885CTSD 1908/4885GRPR 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.